Weiss Ratings Reaffirms “Sell (E+)” Rating for Aardvark Therapeutics (NASDAQ:AARD)

Aardvark Therapeutics (NASDAQ:AARD)‘s stock had its “sell (e+)” rating reaffirmed by equities researchers at Weiss Ratings in a research note issued on Friday,Weiss Ratings reports.

AARD has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Aardvark Therapeutics in a research note on Tuesday, September 23rd. Jones Trading started coverage on shares of Aardvark Therapeutics in a research note on Wednesday, October 1st. They set a “buy” rating and a $33.00 price target for the company. Stifel Nicolaus started coverage on shares of Aardvark Therapeutics in a research note on Monday, September 29th. They set a “buy” rating and a $24.00 price target for the company. Bank of America dropped their price target on shares of Aardvark Therapeutics from $26.00 to $25.00 and set a “buy” rating for the company in a research note on Thursday, August 28th. Finally, Royal Bank Of Canada dropped their price target on shares of Aardvark Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Thursday, August 14th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.43.

Aardvark Therapeutics Price Performance

Shares of NASDAQ:AARD opened at $10.70 on Friday. The firm has a 50 day simple moving average of $11.50 and a 200 day simple moving average of $11.30. Aardvark Therapeutics has a one year low of $4.88 and a one year high of $19.58.

Aardvark Therapeutics (NASDAQ:AARD) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.14).

Insider Transactions at Aardvark Therapeutics

In other Aardvark Therapeutics news, CFO Nelson Sun acquired 6,000 shares of the company’s stock in a transaction dated Tuesday, September 9th. The shares were bought at an average cost of $8.07 per share, with a total value of $48,420.00. Following the purchase, the chief financial officer directly owned 105,484 shares of the company’s stock, valued at $851,255.88. This trade represents a 6.03% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Tien-Li Lee acquired 10,000 shares of the company’s stock in a transaction dated Monday, September 15th. The stock was acquired at an average cost of $9.66 per share, for a total transaction of $96,600.00. Following the completion of the purchase, the chief executive officer directly owned 1,543,384 shares in the company, valued at $14,909,089.44. This trade represents a 0.65% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 36,000 shares of company stock worth $305,630 over the last three months.

Institutional Investors Weigh In On Aardvark Therapeutics

Large investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. acquired a new stake in Aardvark Therapeutics in the first quarter worth $153,000. Adage Capital Partners GP L.L.C. acquired a new stake in Aardvark Therapeutics in the first quarter worth $1,878,000. Cormorant Asset Management LP acquired a new stake in Aardvark Therapeutics in the first quarter worth $6,009,000. Walleye Capital LLC acquired a new stake in Aardvark Therapeutics in the first quarter worth $88,000. Finally, Braidwell LP acquired a new position in shares of Aardvark Therapeutics during the first quarter valued at about $3,755,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.